Insuman Comb 30 (Insulin Human (Rdna))

Insulin human mimics the action of natural pancreatic insulin. After subcutaneous injection it binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production, thereby lowering blood glucose levels.

The dose of Insuman Comb 30 is individualized. A qualified healthcare professional determines the starting amount and subsequent titration based on the patient’s blood‑glucose readings, diet, activity level and overall clinical status. Patients should never adjust the dose without medical guidance.

Insuman Comb 30 may be used in pregnancy or while breastfeeding only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Decisions should be made by the prescribing clinician in consultation with the patient, considering alternative therapies when appropriate.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Insuman Comb 30. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Insuman Comb 30 contains human insulin in a 30/70 ratio (30% rapid‑acting, 70% intermediate‑acting), similar to other premixed products such as Humulin 30. Differences may lie in manufacturing processes, excipients, and regulatory approvals, but clinical efficacy and safety profiles are generally comparable when dosed appropriately.

Store Insuman Comb 30 at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial or pen. Once in use, it may be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining product should be discarded.

Insuman Comb 30 is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be given at consistent times relative to meals, and the injection site should be rotated to reduce the risk of lipodystrophy. Proper technique and needle selection are essential for accurate dosing.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local rash to anaphylaxis. Patients should be educated to recognise early signs of low blood glucose and to seek immediate medical attention for any suspected severe allergic response.

Insuman Comb 30 is contraindicated in individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It should also be avoided in patients with severe hypoglycaemia unawareness or those in whom insulin therapy is not indicated, unless a specialist determines that benefits outweigh risks.